TABLE 2.
Lineage | R | H | MDR-TB | Z | SLIDs | FQs | XDR-TB |
1 (EAI) | 32 (1.5) | 31 (1.6) | 30 (1.5) | 13 (1.0) | 0 (0.0) | 1 (0.2 | 0 (0.0) |
2 (Beijing/East-Asian non-Beijing) | 638 (29.7) | 632 (31.9) | 630 (32.1) | 443 (34.4) | 337 (48.4) | 257 (44.2) | 179 (54.1) |
3 (Delhi-CAS) | 63 (2.9) | 53 (2.7) | 53 (2.7) | 22 (1.7) | 2 (0.3) | 10 (1.7) | 1 (0.3) |
4.1 (Euro-American) | 390 (18.1) | 347 (17.5) | 341 (17.4) | 206 (16.0) | 71 (10.2) | 77 (13.3) | 38 (11.5) |
4.2 (Euro-American) | 199 (9.3) | 191 (9.6) | 189 (9.6) | 122 (9.5) | 48 (6.9) | 49 (8.4) | 25 (7.6) |
4.3 (LAM) | 183 (8.5) | 166 (8.4) | 163 (8.3) | 95 (7.4) | 38 (5.5) | 50 (8.6) | 19 (5.7) |
4.4, 4.5, 4.6 (Euro-American) | 77 (3.6) | 70 (3.5) | 69 (3.5) | 48 (3.7) | 22 (3.2) | 5 (0.9) | 1 (0.3) |
4.7, 4.8, 4.9 (Euro-American) | 555 (25.8) | 483 (24.3) | 476 (24.3) | 333 (25.9) | 175 (25.1) | 131 (22.5) | 67 (20.2) |
5 (West-Africa 1) | 1 (0.0) | 1 (0.1) | 1 (0.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Unknown | 13 (0.6) | 10 (0.5) | 10 (0.5) | 4 (0.3) | 4 (0.6) | 1 (0.2) | 1 (0.3) |
Total | 2151 (97.0) | 1984 (89.5) | 1962 (88.5) | 1286 (58.0) | 697 (31.4) | 581 (26.8) | 331 (15.4) |
Data are presented as n (%). R: rifampicin; H: isoniazid; MDR: multidrug resistant; TB: tuberculosis; Z: pyrazinamide; SLID: second-line injectable drug; FQ: fluoroquinolone; XDR: extensively drug resistant.